Cytokinetics Incorporated

Financials

Cash from operating activities 8.9 M142.5 M299.5 M414.3 M395.9 M510.01 M 510.01 M Cash from investing activities 196.51 M147.78 M262.13 M239.25 M553.1 M16.67 M 16.67 M Cash from financing activities 234.12 M319.98 M516.17 M221.32 M930.61 M524.46 M 524.46 M Free cash flow -2.15 M93.63 M288.17 M412.88 M391.99 M485.2 M 485.2 M

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

CYTK

Financials

Cytokinetics Incorporated

News

BofA raises Cytokinetics stock price target to $67 on Myqorzo

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans

Needham raises Cytokinetics stock price target to $85 on trial outlook

Citizens raises Cytokinetics stock price target to $96 on launch progress

Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript

Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo

Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline

Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?

Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study